CLINICAL_TRIALS ClinicalTrials.gov record update

Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remission

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT04062266
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:28:39.186313+00:00
Published At: 2026-01-13T00:00:00+00:00
Record Updated At: 2026-01-13
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Acute Myeloid Leukemia in Remission", "FLT3 Gene Mutation", "Hematologic and Lymphocytic Disorder", "Acute Myeloid Leukemia", "Minimal Residual Disease Persistence", "Therapy-Related Acute Myeloid Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2026-01-13"
protocolSection.identificationModule.nctId: "NCT04062266"
protocolSection.identificationModule.officialTitle: "Phase II Study of 5-Azacytidine (AZA) + Venetoclax as Maintenance Therapy in Patients With AML in Remission"
protocolSection.statusModule.overallStatus: "ACTIVE_NOT_RECRUITING"
protocolSection.designModule.phases: ["PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.